In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Bayer Diagnostics buys Visible Genetics for $61.4mm in cash

Executive Summary

Bayer Diagnostics is acquiring Visible Genetics (pharmacogenomics) for $61.4mm in cash (about 4.3 times the company's trailing 12-month revenue). Bayer is buying VG's outstanding common shares for $1.50 apiece (a 5.6% premium to market) and its Series A preferred shares at par plus accrued dividends.
Deal Industry
  • In Vitro Diagnostics
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
    • Molecular Diagnostics & Genetic Testing
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Payment Includes Cash

Related Companies